Kymera Therapeutics Income Statement (2019-2026) | KYMR

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
20.34M15.28M9.62M11.51M9.55M16.14M9.47M16.51M4.73M47.88M10.29M25.65M3.74M7.39M22.10M11.48M2.76M2.87M34.37M65.00M
Operating items
Research & Development (Quarter)
38.31M37.53M35.94M41.29M43.88M43.13M42.23M45.77M48.12M-41.41M48.82M12.32M60.41M26.60M26.38M16.26M21.95M244.93M24.96M119.48M
Selling, General & Administrative (Quarter)
10.67M11.74M10.61M11.03M10.56M11.64M12.56M14.13M14.12M14.23M14.37M17.37M15.46M16.33M16.27M17.64M17.34M16.93M20.36M21.13M
Other Operating Expenses (Quarter)
94.38M4.92M46.88M45.21M53.88M62.13M56.00M-161.10M73.20M
Operating Expenses (Quarter)
48.97M49.27M46.55M52.32M54.43M54.77M54.79M59.90M62.24M67.20M68.12M76.58M75.86M88.15M96.53M96.03M95.28M100.77M118.52M140.61M
Operating Income (Quarter)
-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M-97.90M-84.15M-75.61M
EBIT (Quarter)
-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M-97.90M-84.15M-75.61M
Non-operating items
Other Non Operating Income (Quarter)
0.06M0.27M0.25M0.55M1.88M3.65M4.40M4.58M4.64M5.14M9.27M8.86M9.64M10.00M8.85M7.94M10.35M10.91M14.98M14.48M
Net income details
EBT (Quarter)
-270.29M-34.03M-168.49M-85.35M-94.40M-38.69M-112.45M-166.93M-185.39M-68.93M-189.04M-107.96M-221.31M-80.77M-196.41M-218.80M-342.58M-97.90M-494.75M-729.42M
Profit After Tax (Quarter)
-28.58M-33.90M-36.68M-40.26M-43.00M-29.61M-40.93M-38.80M-51.68M-14.37M-48.56M-42.38M-58.46M-70.75M-65.58M-76.61M-80.95M-89.97M-69.23M-64.17M
Income from Continuing Operations (Quarter)
-270.29M-34.03M-168.49M-85.35M-94.40M-38.69M-112.45M-166.93M-185.39M-68.93M-189.04M-107.96M-221.31M-80.77M-196.41M-218.80M-342.58M-97.90M-494.75M-729.42M
Consolidated Net Income (Quarter)
-270.29M-34.03M-168.49M-85.35M-94.40M-38.69M-112.45M-166.93M-185.39M-68.93M-189.04M-107.96M-221.31M-80.77M-196.41M-218.80M-342.58M-97.90M-494.75M-729.42M
Income towards Parent Company (Quarter)
-270.29M-34.03M-168.49M-85.35M-94.40M-38.69M-112.45M-166.93M-185.39M-68.93M-189.04M-107.96M-221.31M-80.77M-196.41M-218.80M-342.58M-97.90M-494.75M-729.42M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-270.29M-34.03M-168.49M-40.26M-43.00M-34.87M-40.93M-38.80M-52.87M-14.37M-48.56M-42.06M-62.49M-70.75M-65.58M-76.61M-82.17M-86.98M-69.23M-61.21M
Additional items
EPS (Basic) (Quarter)
-5.33-0.71-3.26-0.78-0.79-0.65-0.70-0.67-0.90-0.25-0.69-0.58-0.82-0.94-0.82-0.95-0.94-1.03-0.71-0.62
EPS (Diluted) (Quarter)
-5.33-0.71-3.26-0.78-0.79-0.65-0.70-0.67-0.90-0.25-0.69-0.58-0.82-0.94-0.82-0.95-0.94-1.03-0.71-0.62
Shares Outstanding (Quarter)
50.71M47.99M51.65M51.77M54.54M53.93M58.19M58.33M58.42M58.37M70.77M73.06M76.13M75.04M80.15M80.45M87.30M84.49M97.53M98.18M
Shares Outstanding (Diluted) (Quarter)
50.71M47.99M51.65M51.77M54.54M53.93M58.19M58.33M58.42M58.37M70.77M73.06M76.13M75.04M80.15M80.45M87.30M84.49M97.53M98.18M
Shares Outstanding (Entity) (Quarter)
51.26M51.54M51.69M51.85M54.75M55.04M55.28M55.39M55.45M55.59M61.35M61.57M64.75M64.89M65.11M70.56M71.74M81.32M82.18M83.15M
EBITDA (Quarter)
-28.64M-33.99M-36.93M-40.81M-44.88M-38.63M-45.33M-43.38M-57.51M-19.31M-57.83M-50.92M-72.12M-80.75M-74.43M-84.56M-92.52M-97.90M-84.15M-75.61M
Interest Expenses (Quarter)
241.65M0.03M131.55M44.54M49.52M0.06M67.12M123.55M127.88M49.62M131.21M57.03M149.18M0.02M121.98M134.25M250.06M410.60M653.81M